Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Seasonal Influenza Vaccine in Healthy Volunteers
NCT03163342Phase 4Completed
- Sponsor
- Altimmune, Inc.
- Start
- May 2017
- Primary completion
- Nov 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated) in influenza, sponsored by Altimmune, Inc. Primary endpoint: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain at Day 29. Started May 2017; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03163342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163342.